Abstracts that the trend in use of insulin in the Czech republic should be interpreted positively. Similarly, the decrease of sulfonylurea use and the increase of that of metformin are good news. New drugs may offer better treatment options, however, their actual value should be properly assessed in clinical practice.
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Eli Lilly and Company, Indianapolis, IN, USA; 2 University of Virginia Health System, Charlottesville, VA, USA OBJECTIVES: While the patient-reported effects of hypoglycemia have been investigated, little has been done with hyperglycemia. This research was designed to enhance our understanding in this area. METHODS: Using hand-held computers we assessed the acute and cumulative effects of hyperglycemia on mood and cognitive functioning. The sample consisted of 105 adults with type 1 diabetes mellitus who entered their degree of symptoms (tired/sleepy, dry eyes/nose/mouth, sweet taste, need to urinate), cognitive functioning (subtractions, verbal fluency and choice-reaction time tests) and their blood glucose (BG) over four weeks. In addition, they completed several psychometric instruments, including the Diabetes Quality of Life scale. RESULTS: All four symptoms steadily increased as BG rose in the following increments: 110-144mg/dl; 145-180 mg/dl; 181-220 mg/dl; 220-270 mg/dl; Ͼ270mg/dl (p Ͻ .001). Only verbal fluency and mental arithmetic performance worsened with hyperglycemia (BGs Ͼ 270, p Ͻ .005). Individuals with more frequent BGs Ͼ 160mg/dl reported more worry about hyperglycemia, poorer quality of life and more hassles around symptoms and complications, while being less likely to perform non-routine tasks to avoid hyperglycemia. CONCLUSIONS: Both between-and within-subject analyses of acute and cumulative effects demonstrated hyperglycemia has psychological consequences in type 1 diabetes mellitus and may result in less motivation to change routine behaviors to reduce the frequency of hyperglycemia.
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EVALUATION OF A GENERIC QOL INSTRUMENT (KINDL) FOR SELF-ASSESSMENT OF QOL IN SINGAPOREAN CHILDREN WITH DIABETES: A PILOT STUDY
Wee HL 1 , Lee WWR 2 , Li SC 1 , Wee HL 1 1 National University of Singapore, Singapore, Singapore; 2 KK Women and Children's Hospital, Singapore, Singapore OBJECTIVE: To evaluate the validity and reliability of the English version of KINDL (a self-administered generic quality of life instrument originally developed in German) in Singaporean children with diabetes. METHODS: Consecutive patients with diabetes (both types I and II) attending the endocrinology clinic at Kandang Kerbau Women and Children's Hospital were asked to fill in the KINDL questionnaire. Healthy controls were recruited via street interview conducted outside community libraries located in different parts of the island. RESULTS: Thirty-five diabetics (mean age: 14.5 Ϯ 1.48 yrs, 17 males and 18 females) and 34 healthy controls (mean age: 14.5 Ϯ 1.05 yrs, 17 males and 17 females) completed the questionnaire. The overall result showed that diabetic patients have a significantly higher overall score compared to the controls (patient vs. control: 57.0 Ϯ 8.7 vs. 48.8 Ϯ 8.8*, p Ͻ .01). Item reduction of individual domains did not change the overall pattern or the difference in magnitude between scores obtained by the two groups. However, there were improvements (in the vicinity of four to five percent) in overall scores when either the "Personal" or "School" domain was eliminated, indicating the questionnaire is sensitive to the cultural and social differences between Asian and European cultures. The reliability of the instrument as measured by Cronbach's alpha for the six domains for the diabetics ranges from 0.31 to 0.75. CONCLUSION: Although the results appear improbable, they agree with the cultural and social characteristics of Singapore where the educational system is highly stressful. Parents of diabetic children may have lower expectations of their children due to their condition, and hence the perceived better QOL among the diabetic children. However, more data needs to be collected to confirm this observation. *Maximum possible score of 100. 
PDG23
PHARMACEUTICAL AND HOSPITAL EXPENDITURE FOR ANTI-DYSPEPTIC TREATMENT: THE EFFECTS OF THE INTRODUCTION OF A DISEASE MANAGEMENT GUIDELINE
OBJECTIVE:
To highlight the effects incurred in the pharmaco-utilization and in the total expenses for dyspeptic patients by the introduction of a disease-management guideline. METHODS: A retrospective reading of an administrative billing database in the Ravenna Local Health Unit was performed for all health-assisted subjects of 10 GPs who had previously developed and agreed to a clinical guideline to manage dyspeptic patients (Dyspro GPs) as well as by a group of 30 self-regulated GPs (Control GPs). The latter group was selected ex post so as not to be significantly different from the former in terms of personal and patient characteristics. According to anti-dyspeptic treatment, patients were grouped as having had or not prescriptions between 01/01/1999 and 12/31/1999. Dyspeptic subjects were divided as having had or not an earlier anti-dyspeptic treatment (new users/users). The follow-up period lasted 365 days. RESULTS: A total of 51,904 subjects were enrolled, of which 23.1% were enrolled by the Dyspro GPs and 76.9% by the Control GPs. The percentage of dyspeptic patients accounted for 17.6% and 15.0% respectively of subjects enrolled by the Dyspro GPs and the Control GPs. The average age of dyspeptic patients was 57.1 Ϯ 18.6 years and 57.3 Ϯ 18.9 years (p ϭ ns) and the percentage of males was 40.1 and 42.0 (p ϭ ns), respectively in the Dyspro GPs and Control GPs groups. The average drug costs for new users (Ϫ35.76 vs Ϫ38.56) and users (Ϫ107.51 vs Ϫ113.73) was higher as was the average hospitalization cost for new users (Ϫ65.78 vs Ϫ70.84) and users (Ϫ61.13 vs Ϫ87.40) in patients enrolled by the Control GPs. Casualty department access and gastroscopies were not different among patients enrolled by the physician groups. DISCUSSION: Pharmaceutical and hospital expenditures decreased as a consequence of the introduction of a disease-management guideline. Randomized controlled studies showed that rabeprazole in active peptic ulcer is comparable to omeprazole and more effective than ranitidine. We performed economic evaluations of rabeprazole, omeprazole and ranitidine in active gastric and duodenal ulcers. METHODS: A decision tree model (DATA 3.0 Treeage Software Inc.) was applied for retrospective analysis of peptic ulcer healing rate in controlled clinical trials of the three drugs. Direct costs of standard treatment in a hospital setting (six and four weeks for gastric and duodenal ulcers respectively) were calculated. They included hospital bills, investigations and drug-acquisition costs. Costminimization and cost-effectiveness analyses were used to evaluate rabeprazole vs. omeprazole and rabeprazole vs ranitidine respectively. To calculate the incremental costeffectiveness ratio, we utilized the rate of improvement in well-being after two weeks of treatment. RESULTS: The direct costs of rabeprazole and ranitidine in active duodenal ulcer were comparable ($261,21 vs $263,28), but the proton pump inhibitor was significantly more cost-effective than the H2-blocker (incremental cost-effectiveness ratio 0,43 vs 4,66). The difference was due to the higher healing rate and faster effect of rabeprazole. The direct costs of rabeprazole and omeprazole in active duodenal and gastric ulcer were $248,21 vs $266,94 and $311,53 vs $332,77 respectively. The difference was due to lower acquisition cost of rabeprazole. CONCLUSION: Rabeprazole may offer economic advantages over omeprazole and ranitidine in hospital treatment of active gastric and duodenal ulcers.
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PHARMACOECONOMIC ASSESSMENT OF RABEPRAZOLE IN PEPTIC ULCER IN RUSSIA
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ECONOMIC DIFFERENTIATION BETWEEN PPIS IN THE TREATMENT OF REFLUX ESOPHAGITIS RELATED TO GERD
Beard S, Gaffney L RTI Health Solutions, Manchester, UK
